Mendota Financial Group LLC Buys 965 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mendota Financial Group LLC lifted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24,125.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 969 shares of the company’s stock after purchasing an additional 965 shares during the period. Mendota Financial Group LLC’s holdings in Harmony Biosciences were worth $33,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. American Century Companies Inc. increased its stake in shares of Harmony Biosciences by 53.7% in the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock valued at $20,562,000 after buying an additional 238,140 shares during the period. Renaissance Technologies LLC increased its position in Harmony Biosciences by 56.7% in the second quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock worth $17,975,000 after purchasing an additional 215,700 shares during the period. Marshall Wace LLP raised its holdings in Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after purchasing an additional 181,092 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Harmony Biosciences by 27.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after purchasing an additional 140,690 shares during the period. Finally, HealthInvest Partners AB boosted its stake in shares of Harmony Biosciences by 335.2% in the 3rd quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock valued at $6,075,000 after purchasing an additional 116,975 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Monday. Oppenheimer reissued an “outperform” rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. HC Wainwright started coverage on Harmony Biosciences in a research report on Tuesday, December 17th. They issued a “buy” rating and a $75.00 price target on the stock. Cantor Fitzgerald upped their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Finally, Mizuho raised their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $36.42 on Wednesday. The stock’s fifty day simple moving average is $34.21 and its 200 day simple moving average is $34.74. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $2.08 billion, a PE ratio of 17.26, a PEG ratio of 0.60 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same quarter last year, the firm posted $0.63 earnings per share. Harmony Biosciences’s revenue was up 16.0% compared to the same quarter last year. On average, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Buying and Selling at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.